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Summary
 
A hallmark of systemic lupus erythematosus and the MRL murine model for lupus is the pres-
ence of anti–double-stranded (ds)DNA antibodies (Abs). To identify the steps leading to the
production of these Abs in autoimmune mice, we have compared the phenotype and localiza-
tion of anti-dsDNA B cells in autoimmune (MRL
 
1
 
/
 
1
 
 and 
 
lpr/lpr
 
) mice with that in nonauto-
immune (BALB/c) mice. Anti-dsDNA B cells are actively regulated in BALB/c mice as indi-
cated by their developmental arrest and accumulation at the T–B interface of the splenic
follicle. In the MRL genetic background, anti-dsDNA B cells are no longer developmentally
arrested, suggesting an intrinsic B cell defect conferred by MRL background genes. With intact
Fas, they continue to exhibit follicular exclusion; however, in the presence of the 
 
lpr/lpr
 
 muta-
tion, anti-dsDNA B cells are now present in the follicle. Coincident with the altered localiza-
tion of anti-dsDNA B cells is a follicular infiltration of CD4 T cells. Together, these data suggest
that MRL mice are defective in maintaining the developmental arrest of autoreactive B cells and
indicate a role for Fas in restricting entry into the follicle.
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A
 
defining feature of most autoimmune diseases is the
presence of autoantibodies. The factors that account for
the production of autoantibodies in diseased individuals and
their absence in healthy individuals are not clear. Many stud-
ies have examined the characteristics of autoantibodies and
disease pathology after the disease process is well underway;
however, few studies have followed the fate of the autoreac-
tive B cells themselves both before and after initiation of dis-
ease. To understand how tolerance is maintained in the B cell
compartment, we and others have used Ig transgene (Tg)
 
1
 
models that increase the frequency of autoreactive B cells
and allow their fate to be tracked (1–5). Studies using Ig Tgs
directed toward the model Ags hen egg lysozyme (HEL) and
MHC class I have described several fates for autoreactive B
cells in nonautoimmune mice, including clonal deletion, an-
ergy, and receptor editing. The conclusion from these stud-
ies is that the fate of an autoreactive B cell depends on many
factors, including the presence of T cell help and the form
and location of the Ag (1–3, 6). Similar manifestations of
B cell tolerance have also been described using Ig Tg mod-
els for Ags that are targeted in autoimmune diseases such as
SLE (5, 7–13). Given that the nature of the in vivo Ag for
SLE-associated specificities has not been identified, the role
that different forms of Ag, as well as affinity, play in dictating
a deleting versus anergizing phenotype cannot be assigned.
The MRL-
 
lpr/lpr
 
 mouse is a much-studied model of sys-
temic autoimmunity. MRL-
 
lpr/lpr
 
 mice develop a similar
autoantibody profile to SLE patients, with serum Abs di-
rected against many nuclear Ags, such as DNA and histones
(14). MRL
 
1
 
/
 
1
 
 mice, which do not carry the 
 
lpr
 
 mutation
in Fas (15, 16), also develop autoantibodies, although with
delayed kinetics (17). For both MRL-
 
lpr/lpr
 
 and MRL
 
1
 
/
 
1
 
mice, serum autoantibodies are not present at birth; instead
the mice seroconvert as adults (14). What causes this break-
down in tolerance is unclear; potential candidates include
dysregulation of autoreactive B cells, T cells, and/or a dif-
ference in the nature of the Ag(s) being recognized.
Using model Ags, many studies have addressed whether
 
lpr/lpr
 
 mice are globally defective in B and/or T cell toler-
ance. Although one study suggests that negative selection
to high doses of Ag is affected by the 
 
lpr/lpr
 
 mutation (18),
 
1
 
Abbreviations used in this paper:
 
 AFC, antibody-forming cell; ANA, anti-
nuclear antibody; AP, alkaline phosphatase; BM, bone marrow; DN,
double-negative; ds, double-stranded; ELISpot, enzyme-linked immuno-
spot assay; GC, germinal center; HEL, hen egg lysozyme; HN, homoge-
neous nuclear; HRP, horseradish peroxidase; HSA, heat-stable antigen;
MFI, mean fluorescence intensity; MZ, marginal zone; PALS, periarteri-
olar lymphoid sheath; ss, single-stranded; SA, streptavidin; Tg, transgene.  
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the overwhelming conclusion from numerous reports is
that, overall, both B and T cell tolerance is intact in 
 
lpr/lpr
 
mice (19–23). However, all of the examples cited were in-
vestigating tolerance to Ags that are not spontaneously tar-
geted in disease. MRL-
 
lpr/lpr
 
 mice do produce autoanti-
bodies to nuclear Ags, implying that tolerance to specific
self-Ags is no longer intact. Importantly, the steps leading
to this breakdown in tolerance have not been identified.
To understand how anti-DNA B cells are regulated, we
have used the VH3H9 Tg, which was repeatedly isolated
from anti-DNA Abs produced by diseased MRL-
 
lpr/lpr
 
mice (24). The VH3H9 H chain can pair with a variety of
endogenous L chains to generate anti-DNA Abs as well as
non-DNA Abs (25). Therefore, VH3H9 Tg mice give us
the ability to study anti-DNA B cells, in the context of B
cells with other specificities, in both nonautoimmune and
autoimmune environments. Using the VH3H9 Tg on a
nonautoimmune (BALB/c) background, we have identi-
fied a population of anti–double-stranded (ds)DNA B cells
that persist in the periphery (10). These cells are develop-
mentally arrested and have a shortened life span. Addition-
ally, they localize to the T–B interface of the splenic folli-
cle. These features of anergy are similar to those of anergic
anti-HEL B cells in a diverse repertoire, with the exception
that anti-HEL B cells are reported as not being develop-
mentally arrested (3, 26, 27).
The presence of anti-DNA Abs in MRL-
 
lpr/lpr
 
 mice
suggests that the regulation of anti-DNA B cells is no
longer intact; however, it does not tell us how either MRL
genes or the 
 
lpr/lpr
 
 mutation influence the loss of tolerance.
Although it is clear that there are distinct MRL and 
 
lpr
 
contributions to autoimmunity, their precise consequences
for the fate of autoreactive B cells have not been defined.
To determine more specifically how the regulation of anti-
dsDNA B cells breaks down in the autoimmune environ-
ment, the VH3H9 Tg was bred onto the MRL-
 
lpr/lpr
 
 and
MRL
 
1
 
/
 
1
 
 backgrounds and the fate of anti-dsDNA B cells
monitored. Comparing the phenotype of anti-dsDNA B cells
in MRL mice to that in BALB/c mice allows us to identify
differences that may account for the production of anti-
dsDNA Abs in autoimmune mice. Additionally, by exam-
ining VH3H9 MRL-
 
lpr/lpr
 
 mice before and after anti-
dsDNA Ab is detected in the serum, we may be able to
correlate phenotypic changes with the onset of seroconver-
sion. Finally, by comparing the fate of anti-dsDNA B cells in
MRL-
 
lpr/lpr
 
 with MRL
 
1
 
/
 
1
 
 mice, the contribution of Fas
in the elimination of autoreactive B cells may be identified.
In this study, we document several changes in the status of
anti-dsDNA B cells in both MRL
 
1
 
/
 
1
 
 and MRL-
 
lpr/lpr
 
mice that precede the expression of serum autoantibodies.
MRL
 
1
 
/
 
1
 
 and MRL-
 
lpr/lpr
 
 mice exhibit a defect in main-
taining the developmental arrest of anti-dsDNA B cells. In
MRL-
 
lpr/lpr
 
 mice, two additional changes have been identi-
fied: the anti-dsDNA B cells are now able to enter the B cell
follicle, and the T/B lymphoid architecture is disrupted be-
fore seroconversion. Thus, this study reveals potential mech-
anisms by which the MRL genetic background and the 
 
lpr
 
mutation in Fas contribute to autoantibody production.
 
Materials and Methods
 
Mice
 
BALB/c mice were purchased from Harlan Sprague-Dawley,
Inc. MRL-
 
lpr/lpr
 
 and MRL
 
1
 
/
 
1
 
 mice were purchased from The
Jackson Laboratory. VH3H9 Tg mice have been described previ-
ously (4). The VH3H9 Tg mice have been backcrossed onto the
BALB/c and MRL backgrounds for at least 9 and 17 generations,
respectively, and have been bred and maintained in the animal fa-
cility at The Wistar Institute. VH3H9 MRL-
 
lpr/lpr
 
 mice defi-
cient in the JH locus were obtained from M. Shlomchik (Yale
University, New Haven, CT [28]). In all cases, age-matched
BALB/c mice and/or Tg
 
2
 
 
 
littermates were used as controls. The
presence of the VH3H9 Tg was determined by PCR amplifica-
tion of tail DNA with primers specific for VH3H9 (4).
 
Antinuclear Antibody Assay
 
The presence of antinuclear Abs (ANAs) in serum was detected
using permeabilized HEP-2 cells as the substrate (Antibodies In-
corporated). Manufacturer’s instructions were followed with se-
rum samples tested at a 1:100 dilution. Anti-homogeneous nuclear
(HN) ANA binding and ANA titers were detected with a combi-
nation, defined as total Ig, of FITC-conjugated goat anti–mouse
Ig(H
 
1
 
L) and anti–mouse IgM reagents (Southern Biotechnology
Associates). To test for the presence of 
 
l
 
 ANAs, an FITC-conju-
gated goat anti–mouse 
 
l
 
 reagent (Southern Biotechnology Associ-
ates) or LS136-biotin (anti-
 
l
 
1; gift of Garnett Kelsoe, Duke Uni-
versity, Durham, NC) followed by streptavidin (SA)-FITC (Fisher
Biotech) was used. The samples were then visualized under a fluo-
rescent microscope and scored blind, without knowledge of age
or genotype of the mice. The results using the monoclonal LS136
and polyclonal anti-
 
l
 
 reagents were comparable.
 
ANA Detection in Seroconversion.
 
Sera were tested from six lit-
ters of mice. These mice were bled once a week between 6 and
16 wk of age. These serial samples were tested, in the protocol
described above, for the presence of total Ig anti-HN and Ig
 
l
 
ANAs. The first positive bleed was considered the seroconversion
time point.
 
ANA Titers.
 
The anti-HN seroconversion time points of a
subset of Tg
 
2
 
 
 
and VH3H9 MRL-
 
lpr/lpr
 
 mice were examined for
total Ig ANA titers. In each case, the time point was 10 wk of
age. These samples were tested at an initial 1:100 dilution and at
serial 10-fold dilutions. The serum titer was defined as the recip-
rocal of the last dilution at which positive staining was seen.
 
Cell Preparations
 
Bone marrow (BM), spleen, and LN cells were removed from
VH3H9 Tg and Tg
 
2
 
 
 
mice. Single-cell suspensions were prepared
and, where necessary, erythrocytes were removed by hypotonic lysis.
 
Identification of VH3H9/V
 
l
 
1 B Cells
 
Because the VH3H9 H chain Tg has been shown to be a good
excluder of endogenous H chain rearrangement in the BALB/c
background, we have followed the fate of anti-dsDNA B cells in
VH3H9 Tg mice using anti-
 
l
 
–specific reagents (4). Additionally,
the restricted use of VH3H9 by 
 
l
 
1
 
 cells was confirmed using
JH
 
2
 
/
 
2
 
 MRL-
 
lpr/lpr
 
 mice (28). Several different reagents were used
to track 
 
l
 
1
 
 and 
 
l
 
1
 
1
 
 B cells (LS136, R11-153, JC5, and R26-46).
Using these reagents and flow cytometry we have shown that the
majority of 
 
l
 
1
 
 B cells in VH3H9 Tg mice are 
 
l
 
1 (10). Therefore, 
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we are able to follow VH3H9/V
 
l
 
1 B cells in MRL mice using
anti-pan 
 
l
 
 reagents.
 
Flow Cytometry Analysis
 
Cells (5 
 
3
 
 10
 
5
 
)
 
 
 
were surface stained according to standard proto-
cols (29). The following Abs were used: RA3-6B2–FITC, –PE, or
–biotin (anti-B220), R11-153–FITC (anti-V
 
l
 
1), R26-46–FITC
(anti-V
 
l
 
 total), R8-140–PE (anti-Ig
 
k
 
), 1D3-FITC or -biotin
(anti-CD19), 7G6-FITC (anti-CD21/35), Cy34.1-FITC (anti-
CD22), B3B4-FITC (anti-CD23), 3/23-FITC (anti-CD40),
Mel-14–FITC (anti-CD62L, L-selectin), M1/69-FITC (anti–heat-
stable antigen [HSA]), and IM7-FITC (anti-CD44) (PharMingen);
7E9-FITC (anti-CD21/35; gift of A. Naji, University of Penn-
sylvania, Philadelphia, PA); LS136-biotin (anti-V
 
l
 
1; gift of G.
Kelsoe) and JC5.1-PE (anti-V
 
l
 
 total; gift of J. Kearney, Uni-
versity of Alabama, Birmingham, AL); polyclonal anti-IgM–PE
and SBA-1–PE (anti-IgD; Southern Biotechnology Associates);
SA-Red670 (GIBCO BRL); SA-FITC (Fisher Biotech); and
SA-PE (Vector Laboratories).
All samples were analyzed on a FACScan™ flow cytometer
(Becton Dickinson) using CellQuest software. 15,000–40,000
events were collected for each sample and gated for live lympho-
cytes based on forward and side scatter.
In analyzing the cell surface phenotype, it became apparent
that SA-Red670 binds to B cells from MRL-
 
lpr/lpr
 
 mice. The re-
agent does not bind to conventional T cells in MRL-
 
lpr/lpr
 
 mice,
but does bind to 
 
z
 
10% of the B220
 
1
 
CD3
 
1
 
CD4
 
2
 
CD8
 
2
 
 (dou-
ble-negative [DN]) T cells that accumulate. This binding segre-
gates with the mouse strain: BALB/c and C57BL/6 B cells do not
bind to SA-Red670, whereas MRL-
 
lpr/lpr
 
 and MRL
 
1
 
/
 
1
 
 B cells
do bind (data not shown). SA-Red670 binding is not due to the
SA in the conjugate because neither SA-FITC nor SA-PE binds
to MRL-derived cells (data not shown). Because Red670 is com-
posed of PE plus a Cy5 residue (30), this suggests that Cy5 medi-
ates the binding. It is unclear what Red670 binds on the B
cell, but it does not appear to be mediated through Ig since the
Ig
 
low
 
 cells have the same amount of Red670 binding as the Ig
 
high
 
cells (data not shown). Because all B cells in MRL mice and only
a small fraction of DN T cells bind to SA-Red670, in some
experiments we have used SA-Red670 as a marker to enrich for
B cells. To identify B cells specifically, a second B cell marker
that is absent on DN T cells, such as CD19 or Ig, was used to
identify the B cells.
 
Immunohistochemistry
 
Spleens were suspended in OCT, frozen in 2-methyl-butane
cooled with liquid nitrogen, sectioned, and fixed with acetone.
The spleen sections were stored at 
 
2
 
20
 
8
 
C and then stained ac-
cording to the protocol described (31). In brief, the sections were
blocked using PBS/5% normal goat serum (Sigma Chemical
Co.)/0.1% Tween-20 and then stained with GK1.5-biotin (anti-
CD4), 53-6.7–biotin (anti-CD8), 30H12-FITC (anti–Thy-1.2)
(grown as supernatants), Cy34.1-FITC (anti-CD22), 281-2
(anti–syndecan-1) (PharMingen), MOMA-1 (anti–marginal me-
tallophilic macrophages; Bachem), and/or anti-Ig
 
l
 
–alkaline phos-
phatase (AP) (Southern Biotechnology Associates). Streptavidin–
horseradish peroxidase (HRP) or -AP (Southern Biotechnology
Associates), polyclonal anti–rat-HRP (Jackson ImmunoResearch
Laboratories), MAR18.5-biotin (anti–rat Ig, grown as supernatant),
and anti-FITC–AP (Sigma Chemical Co.) or anti-FITC–HRP
(Chemicon) were used as secondary Abs. HRP and AP were de-
veloped using the substrates 3-amino-9-ethyl-carbazole (3-AEC)
and Fast Blue BB base (Sigma Chemical Co.), respectively.
 
Enzyme-linked Immunospot Assay
 
Splenic B cells were plated at 4 
 
3
 
 10
 
5
 
 cells/well and diluted
serially 1:4 in Multiscreen HA mixed cellulose ester membrane
plates (Millipore) coated with unlabeled goat anti–mouse total Ig
(Southern Biotechnology Associates). The Ig secreted by the
plated cells was detected by AP-conjugated goat anti–mouse total
Ig or Ig
 
l
 
 as secondary Abs (Southern Biotechnology Associates)
and visualized using NBT/BCIP substrate (nitroblue tetrazolium/
5-bromo-4-chloro-3-indolyl phosphate; Sigma Chemical Co.).
 
Statistical Analysis
 
Statistical significance was determined using an unpaired non-
parametric test and Instat software.
 
Results
 
In this study, we have used the VH3H9 Tg to track a
specific population of anti-dsDNA B cells, in the context of
a diverse repertoire, and compare their fate in nonautoim-
mune and autoimmune environments. Transfection and hy-
bridoma analyses have shown that the germline V
 
l
 
1 L chain
pairs with the VH3H9 H chain to generate an anti-dsDNA
ANA
 
1
 
 Ab (25, 32). Using anti-
 
l
 
–specific reagents, we have
followed B cells of this specificity in terms of serum Ab ex-
pression, surface phenotype, splenic localization, and ability
to differentiate into antibody-forming cells (AFCs).
 
The Kinetics of Seroconversion in MRL-lpr/lpr Mice.
 
As a
first step in studying VH3H9 MRL-
 
lpr/lpr
 
 mice, we exam-
ined the overall rate at which ANAs appeared in the serum.
An age-matched cohort of Tg
 
2
 
 and VH3H9 MRL-lpr/lpr
mice was bled weekly from age 6 to 16 wk. The sera were
tested for the presence of ANAs using reagents to detect
total Ig, and scored as positive when they showed an HN
staining pattern. This ANA pattern is found in a high fre-
quency of SLE serum and correlates with the presence of
anti-dsDNA, antihistone, and antichromatin Abs (33). Fig.
1 A shows that Tg2 MRL-lpr/lpr mice became serum HN
ANA1 at approximately the same time (10.1 6 3.0 wk) as
VH3H9 MRL-lpr/lpr mice (9.1 6 2.0 wk; P 5 0.2). To
test if the VH3H9 Tg alters the amount of ANA in the se-
rum, ANA titers were determined for a subset of the mice
(Fig. 1 B). Again, no difference was detected between Tg2
and VH3H9 MRL-lpr/lpr mice. Likewise, Fig. 1 C shows
that the VH3H9 MRL-lpr/lpr mice seroconvert to Igl
ANA1 at an average of 9.2 6 1.4 wk, the same time when
total HN ANAs appear in the serum (9.1 6 2.0 wk). Within
the time-frame analyzed (ages 6.0–43.5 wk), the VH3H9/l1
specificity was not detected in serum from MRL1/1 mice
(data not shown). The fact that most Tg2 MRL-lpr/lpr mice
failed to seroconvert to Igl ANA1 is consistent with data
showing that the overwhelming majority of ANAs in Tg2
MRL-lpr/lpr mice use the more abundant Igk L chains (34).
Given that VH3H9/Vl1 ANAs arise with the same kinetics
as other ANAs in both Tg2 and Tg1 MRL-lpr/lpr mice,
VH3H9/Vl1 B cells appear to be a good model for fol-
lowing the fate of ANA B cells in general.
Anti-dsDNA B Cells in VH3H9 Mice Show Evidence of Ag
Encounter in the BM. Having established the kinetics of1802 MRL/lpr Defect in B Cell Developmental Arrest and Follicular Exclusion
seroconversion, we proceeded to compare the phenotype
of anti-dsDNA B cells in mice that are serum ANA1 (.9 wk
MRL-lpr/lpr) with mice that are ANA2 (,9 wk MRL-lpr/lpr,
MRL1/1, and BALB/c). Using l-specific reagents and
flow cytometry, we have previously shown that anti-dsDNA
B cells are present in the periphery of nonautoimmune
(BALB/c) mice with a decreased level (four- to fivefold)
of surface Ig relative to Tg2 B cells (10). Likewise, Igl1
B cells are also present in the spleen and LNs of VH3H9
MRL-lpr/lpr and VH3H9 MRL1/1 mice, with the same
four- to fivefold decreased level of surface Ig compared
with Igls in Tg2 mice (Fig. 2 B, and data not shown). In-
terestingly, when Ig levels are compared for Igl1 cells in
the BM, the Ig level is also reduced, and to a similar extent,
in VH3H9 MRL-lpr/lpr, VH3H9 MRL1/1 (Fig. 2 A),
and VH3H9 BALB/c mice (10). We and others have inter-
preted a low level of Ig to be an indication of Ag encounter
(3, 10–12, 35–38). Additionally, the extent of receptor
downmodulation has been correlated with the available con-
centration of self-Ag (39, 40). Thus, the VH3H9/Igl B cells
in all backgrounds tested encounter their Ag, and this inter-
action first takes place in the BM.
Cell Surface Phenotype of MRL1/1 and MRL-lpr/lpr B Cells
Differs from BALB/c B Cells. We next were interested in
determining how encounter with Ag would affect the pheno-
type of the autoreactive cells from MRL1/1, MRL-lpr/lpr,
Figure 1. The VH3H9 Tg does not change the seroconversion time point or titer of ANAs but does increase serum l ANA frequency. An age-matched
cohort of Tg2 (s) and VH3H9 (d) MRL-lpr/lpr mice was bled weekly from the age of 6 to 16 wk. Sera were tested for the presence of ANAs by immu-
nofluorescence. (A) Symbols represent individual mice at the age when anti-HN ANAs first appear. Tg2 MRL-lpr/lpr mice became serum ANA1 at ap-
proximately the same time (10.1 6 3.0 wk) as VH3H9 MRL-lpr/lpr mice (9.1 6 2.0 wk; P 5 0.2). n 5 25 mice of each genotype. (B) ANA titers were
determined for the seroconversion time point (10 wk) of a subset of mice (n 5 6 mice of each genotype). The serum titer is defined as the reciprocal of the
last dilution at which positive staining was seen. No difference was detected between Tg2 and VH3H9 MRL-lpr/lpr mice. (C) Serum samples were tested
for the appearance of l ANAs. Symbols placed above the dotted line represent mice at the age when l ANAs were first detected. Below the dotted line are
symbols representing mice that failed to show l ANAs by 15 wk of age. n 5 17 Tg2 MRL-lpr/lpr, n 5 18 VH3H9 MRL-lpr/lpr mice.
Figure 2. VH3H9/l anti-dsDNA B cells are present with a reduced Ig density: (A) BM and (B) spleen in (left) MRL-lpr/lpr and (right) MRL1/1 mice.
Dot plots are graphed on a log scale, and mean fluorescence intensity (MFI) is given for the l1 cells in the boxed region. n 5 7 mice of each genotype.1803 Mandik-Nayak et al.
and BALB/c mice. However, before the analysis of VH3H9
Tg anti-dsDNA B cells, we noted differences among the
three background strains of mice in terms of B cell expres-
sion levels of several cell surface markers. Although a simi-
lar pattern of expression for all sets of mice was observed
for the majority of markers, including B220 (Fig. 3 A),
HSA, CD22, and CD44 (data not shown), there were no-
table exceptions in L-selectin, CD23, and CD21/35. The
proportion of L-selectinlow B cells is increased in MRL1/1
and MRL-lpr/lpr mice compared with BALB/c mice (Fig.
3 A). Decreased levels of L-selectin can indicate activation,
suggesting that activated B cells are accumulating in
MRL1/1 and MRL-lpr/lpr mice (41, 42). Additionally, as
has been previously reported, CD23 levels are also de-
creased on MRL-lpr/lpr B cells and this decrease is more
apparent as the mice age (43; Fig. 3 A). A decrease in
CD21/35 expression has been reported in MRL-lpr/lpr
mice (44) as well as SLE patients (45–47). We also observe
a twofold decrease in CD21/35 expression on a portion of
the B cells in MRL-lpr/lpr mice compared with BALB/c
and MRL1/1 mice. However, in our analysis, the most
striking difference in the MRL mice both with and with-
out the lpr mutation when compared with the BALB/c
mice is the dramatic increase in CD21/35high cells (Fig. 3 A).
This peak of CD21/35high cells, which are also IgMhigh
(data not shown), accumulates with age in the MRL-lpr/lpr
mice. Because CD23lowCD21/35highIgMhigh is reminiscent
of the phenotype assigned to marginal zone (MZ) B cells
(48), we are in the process of quantitating whether MRL
mice have an exaggerated MZ area.
Anti-dsDNA B Cells Are No Longer Developmentally
Arrested in MRL1/1 and MRL-lpr/lpr Mice. With differ-
ences among the three background strains noted, the de-
velopmental status of the anti-dsDNA B cells in VH3H9
MRL1/1, VH3H9 MRL-lpr/lpr, and VH3H9 BALB/c
mice was compared using flow cytometry and a panel of
cell surface markers. Previously, we have shown that anti-
dsDNA B cells in VH3H9 BALB/c mice are developmen-
tally arrested and show signs of activation (10). To examine
the cell surface phenotype of splenic anti-dsDNA B cells,
the relative expression levels of B220, HSA, CD21/35,
CD22, CD23, and CD44 (29, 49–53) on VH3H9/l B cells
were compared with those on Tg2 B cells in BALB/c (Fig.
3 B), MRL1/1 (Fig. 3 B), and MRL-lpr/lpr (Fig. 3 C)
mice. The l1 B cells in Tg2 MRL1/1 (Fig. 3 B), MRL-
lpr/lpr (Fig. 3 C), and BALB/c (10) mice have equivalent
levels of all surface markers tested, suggesting that there is
nothing inherently different about Igl1 B cells. In contrast
and as previously reported, anti-dsDNA B cells from
VH3H9 Tg BALB/c mice appear developmentally arrested
in that they express a low level, relative to mature splenic
B cells, of B220 (decreased twofold), CD21/35 (decreased
threefold), CD22 (decreased twofold), and CD23 (decreased
twofold), an intermediate level of HSA (increased twofold),
and an elevated level of CD44 (increased fourfold) (10; Fig.
3 B). Importantly, VH3H9/l B cells on the MRL1/1
and MRL-lpr/lpr background are no longer developmen-
tally arrested: they express mature levels of B220, HSA,
CD22, and CD44 (Fig. 3, B and C). Additionally, VH3H9/l
MRL1/1 B cells express mature levels of CD23 (Fig. 3 B);
however, in the MRL-lpr/lpr mice, CD23 is not a useful
marker for maturation, given that the level of CD23 is dra-
matically reduced on all MRL-lpr/lpr B cells as the mice
age (43; Fig. 3 A). The surface phenotype of VH3H9/l
B cells was also compared in MRL-lpr/lpr mice both before
and after seroconversion to determine if autoantibody pro-
duction is marked by a change in cell surface phenotype.
Igl1 B cells from both ANA2 (age 4–7 wk) and ANA1
(age 8–14 wk) VH3H9 MRL-lpr/lpr mice are phenotypi-
cally mature (Fig. 3 C). One drawback of this analysis is
that most of the markers tested are lost on B cells that have
differentiated into AFCs. Thus, although we may be miss-
ing AFCs in the flow cytometry analysis, the majority of
the VH3H9/l B cell population is indistinguishable be-
tween ANA2 and ANA1 MRL-lpr/lpr mice.
While several cell surface markers suggest that anti-
dsDNA B cells in MRL1/1 and MRL-lpr/lpr mice are no
longer developmentally arrested, CD21/35 levels are de-
creased on VH3H9/l1 B cells, although not to the extent
they are in the BALB/c background (decreased one- to
twofold in MRL mice compared with threefold in BALB/c
mice; Fig. 3, B and C). The reduced level of CD21/35 is
not due to complement binding that in turn could block
the Ab binding site, because staining with two different
anti-CD21/35 Abs (7G6, which binds to the complement-
binding site, and 7E9, which does not [54, 55]) gave similar
results (data not shown). Why CD21/35 levels remain de-
creased on VH3H9 MRL1/1 and MRL-lpr/lpr l1 B cells,
despite normal levels of other developmental markers
(B220, HSA, and CD22) is not clear. One possibility is that
only those B cells expressing low levels of CD21/35 persist
after negative selection, given that CD21/35 is a corecep-
tor for signals through the Ig receptor (56). A similar expla-
nation has been described for the reduced levels of the
CD8 coreceptor seen on self-reactive anti-HY TCR Tg
T cells present in the periphery of male mice (57). Another
possibility is that reduced CD21/35 levels reflect activation
due to Ag encounter (44). Ig Tg B cells specific for model
Ags, where Ag exposure can be controlled, may help to de-
termine if Ig downmodulation in the presence of Ag is ac-
companied by a decrease in CD21/35.
One scenario that could account for the more advanced
maturation of VH3H9/l1 B cells in MRL as opposed to
BALB/c mice is that they encounter Ag at a later develop-
mental stage in the BM and thus their maturation goes un-
impeded. As an indication of Ag encounter, the level of
surface Ig on the l1 B cells in the BM of VH3H9 and Tg2
BALB/c, MRL1/1, and MRL-lpr/lpr mice was com-
pared. As is shown in Fig. 3 D, the level of Ig on Tg2 B cells
increases as the B cells mature from a CD22low to a
CD22high stage. If the VH3H9/l1 B cells in the different
genetic backgrounds are encountering Ag at a later stage,
we would have predicted that the level of Ig would be
higher on the less mature (CD22low) B cells in the VH3H9
Tg MRL mice and then decrease once they have encoun-
tered Ag. However, the level of Ig on VH3H9/l1 B cells1804 MRL/lpr Defect in B Cell Developmental Arrest and Follicular Exclusion
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from all three backgrounds is low at the CD22low stage and
remains low at the CD22high stage, suggesting that these B cells
have all encountered Ag at an immature stage. This encoun-
ter with Ag does not halt the maturation of the B cells: in
BALB/c mice, the VH3H9/l1 B cells continue to develop
to a slightly more mature stage as indicated by intermediate
levels of HSA, B220, CD22, and CD23 (10; and Fig. 3 B),
whereas in MRL mice (1/1 and lpr/lpr), the splenic B cells
appear fully mature (Fig. 3, B and C).
To confirm that the cells we are following are using the
VH3H9 Tg, we have repeated our experiments using
VH3H9 MRL-lpr/lpr mice deficient at the JH locus (JH2/2
[28]). As B cells in VH3H9 JH2/2 mice are unable to rear-
range endogenous H chain loci, the only H chain they
express is the VH3H9 Tg. The results from VH3H9 MRL-
lpr/lpr mice with and without an intact JH locus were in-
distinguishable in terms of phenotypic analysis of BM and
splenic VH3H9/Vl B cells (data not shown).
Altered Localization of Anti-dsDNA B Cells in MRL-lpr/lpr
Mice. Given the changes in developmental maturity of
anti-dsDNA B cells in BALB/c versus MRL mice, we next
looked to see what effect these changes have on the B cells’
splenic localization. For the most part, B and T cells are lo-
cated in discrete areas in the spleen, called the B cell follicle
and periarteriolar lymphoid sheath (PALS), respectively.
Previously, using Ig Tg mice, we and others have shown
that anergic B cells localize to the T–B interface of the
splenic follicle (10, 27). One hypothesis to account for this
localization is that anergic B cells continually encountering
Ag are at a competitive disadvantage for follicular space (27,
58). Another hypothesis is that the location of the B cells is
dependent on the amount of Ag exposure, not competition
with other naive B cells (39, 40). In both models, B cells
encountering Ag move to the T–B interface, where they
can interact with T cells. Immature B cells are also reported
to first appear at the T–B interface in the spleen (59).
Given that the VH3H9/l BALB/c B cells that localize
to the T–B interface are both immature and have encoun-
tered Ag, we have been unable to distinguish which of
these features is responsible for their localization (10; and
Fig. 4 A). However, on the MRL1/1 and MRL-lpr/lpr
backgrounds, VH3H9/l B cells are no longer develop-
mentally arrested, providing an opportunity to separate
maturation status from Ag encounter. Igl1 B cells in Tg2
mice from autoimmune and nonautoimmune backgrounds
are scattered throughout the splenic follicle (10; Fig. 4, A
and B). However, similar to their counterparts in the
BALB/c background, VH3H9/l B cells from MRL1/1
mice localize to the T–B interface (Fig. 4 A). Therefore,
follicular localization is not dependent on the developmen-
tal status of the autoreactive B cells, at least in MRL1/1
mice; rather, we suggest it is a consequence of Ag en-
counter.
In striking contrast to the VH3H9/l MRL1/1 B cells,
VH3H9/l1 B cells in the MRL-lpr/lpr background are not
localized to the T–B interface; instead, they are located
within the B cell follicle (Fig. 4 A). This pattern of localiza-
tion is seen in mice as early as 4 wk of age, before their
specificity is detectable in the serum. Identical results for
localization of anti-dsDNA B cells were obtained using
VH3H9 MRL-lpr/lpr mice with and without an intact JH
locus, confirming that the cells we are following use the
VH3H9 Tg (data not shown). Thus, while indistinguishable
by developmental status, anti-dsDNA B cells in VH3H9
Figure 3. Phenotypic analysis of Tg2 and VH3H9
(A–C) splenic and (D) BM B cells in age-matched
BALB/c, MRL1/1, and MRL-lpr/lpr mice. (A) Tg2
mice. Histograms show staining of total B cell popula-
tion (gated on B2201Ig1 cells). Percentages are given
for the indicated gates on representative plots. There is
an exaggerated population of CD21high cells (MFI .
200) present in MRL1/1 (32.9 6 11.5%) and MRL-
lpr/lpr (40.1 6 9.9%) compared with BALB/c (7.9 6
3.1%) mice (P , 0.0001). CD23 levels decrease on
MRL-lpr/lpr B cells as the mice age (percentage of
CD23low B cells at 4–7 wk, 48 6 10.6% vs. at 8–14 wk,
70.4 6 8.7%; P 5 0.03). There is also an increased
population of CD23low B cells in MRL1/1 mice
(MRL1/1, 48 6 11.3% vs. BALB/c, 16.4 6 3.4%; P 5
0.016), although not to the extent in 8–14 wk MRL-
lpr/lpr mice (70.4 6 8.7%; P 5 0.0003). The propor-
tion of L-selectinlow B cells is increased in MRL-lpr/lpr
(38.8 6 13.6%) and MRL1/1 (38.4 6 13.9%) com-
pared with BALB/c (23.5 6 4.8%) mice (P 5 0.009).
VH3H9/l B cells in (B) MRL1/1, BALB/c, and (C) MRL-lpr/lpr spleen. Histograms are gated on the total B cell population (thin line) and Igl1 pop-
ulation (bold line). The underlaid histograms (thin line) were scaled down to allow for comparison to the l1 B cells (which comprise z10% of the total
B cell population). The majority of markers show that VH3H9/l B cells in MRL1/1 and MRL-lpr/lpr mice, unlike in BALB/c mice, are no longer de-
velopmentally arrested; however, CD21/35 levels are decreased. VH3H9 BALB/c, VH3H9 MRL1/1, and VH3H9 MRL-lpr/lpr mice at 4–7 wk are l
ANA2, whereas VH3H9 MRL-lpr/lpr mice at 8–14 wk are l ANA1. VH3H9/l B cells in MRL-lpr/lpr and MRL1/1 spleens are developmentally ma-
ture regardless of the mouse’s ANA status. (D) BM B cells were stained with CD22 and Igl. VH3H9/l B cells are Iglow at the CD22low stage (VH3H9/
Igl MFI, 50 vs. Tg2 Igl MFI, 200) and do not decrease as the B cells mature (VH3H9/Igl MFI, 68 vs. Tg2 Igl MFI, 480), suggesting an encounter
with Ag at an early developmental stage. Note that there is a decrease in the CD22high population (23 to 6%) in MRL-lpr/lpr mice, with and without the
VH3H9 Tg. This is consistent with a previous report that documents a decrease in the frequency of mature B cells in the BM of MRL-lpr/lpr mice (ref-
erence 87). All graphs are plotted on a log scale. n 5 7 mice at each age range for each genotype.1806 MRL/lpr Defect in B Cell Developmental Arrest and Follicular Exclusion
MRL1/1 and VH3H9 MRL-lpr/lpr mice exhibit differ-
ent splenic localizations.
Disrupted Architecture in MRL-lpr/lpr Mice. Disruptions
in the splenic architecture of MRL-lpr/lpr mice have been
known for some time and have been attributed to the ac-
cumulation of CD31B2201CD42CD82 (DN) T cells. It
has been reported that these DN T cells are located be-
tween the T and B cell areas in the follicles of older MRL-
lpr/lpr mice (60, 61). To confirm this, MRL-lpr/lpr spleen
sections were stained with anti-B220 and anti-CD3, and
coexpressing cells were identified by immunofluorescence.
In agreement with previous studies, the B2201CD31 cells
were located in discrete areas between the PALS and what
remained of the B cell follicle (data not shown).
Figure 4. Localization of Igl1 B cells. (A) Spleen sections from Tg2, VH3H9 BALB/c, VH3H9 MRL1/1, and VH3H9 MRL-lpr/lpr mice were
stained with Abs against (top) CD22 and Igl or (bottom) CD4 and Igl. In Tg2 mice of all three backgrounds, the Igl1 cells are scattered throughout the
B cell follicle. The follicle shown in the figure is from a Tg2 MRL1/1 spleen. Igl1 cells in VH3H9 MRL1/1 mice, like those in VH3H9 BALB/c,
accumulate at the T–B interface. However, the VH3H9/l B cells in MRL-lpr/lpr mice are found in the B cell follicle. Interestingly, CD41 cells are also
scattered in the B cell area with the l1 B cells. Mice shown are 5 wk of age. (B) Spleen sections from (top) Tg2 MRL-lpr/lpr and (bottom) VH3H9
MRL-lpr/lpr mice stained with Abs against (left) CD22 and Igl, (middle) CD4 and Igl, or (right) CD22 and syndecan-1 (AFCs). In the majority of fol-
licles, VH3H9/Igl AFCs are found in the PALS, although some follicles did not have syndecan-11 cells. AFCs in Tg2 MRL-lpr/lpr mice are also found
in the PALS. AFCs are first detectable at 8 wk, and mice shown are 10 wk of age. Original magnification: 3100 (n 5 10 mice of each genotype).1807 Mandik-Nayak et al.
In addition to the disruption in splenic architecture
caused by DN T cells, we have identified a novel histolog-
ical feature of MRL-lpr/lpr mice that is evident even before
the emergence of DN T cells. In contrast to the usual seg-
regation of B and T cells, CD4 T cells in VH3H9 MRL-
lpr/lpr mice do not localize exclusively to the T cell area: a
subpopulation of CD4 T cells are in the B cell follicle (Fig.
4 A). To examine this altered CD4 localization more closely,
spleen sections were stained with MOMA-1, a marker for
MZ macrophages, and either CD22, CD4, or CD8 (Fig.
5, A and B). In both BALB/c and MRL1/1 spleens, with
and without the VH3H9 Tg, distinct B and T cell areas are
present with few to no CD4 or CD8 T cells in the B cell
area (Fig. 5 A). However, in VH3H9 MRL-lpr/lpr spleens,
although distinct B and T cell areas are present, there is also
a subpopulation of CD4 T cells scattered throughout the fol-
licle (Fig. 5 B). CD4 T cells have been found in the B cell
follicle in the context of germinal centers (GCs [62]).
Figure 5. Disrupted architecture in MRL-
lpr/lpr mice. (A) Spleen sections from (top) Tg2
BALB/c, (middle) Tg2 MRL1/1, and (bot-
tom) Tg2 MRL-lpr/lpr mice were stained with
Abs against MOMA-1 (MZ metallophilic mac-
rophages) and (left) CD22 (B cells), (middle)
CD4 (T cells), or (right) CD8. In MRL-lpr/lpr
mice, CD4 T cells are present scattered in the B
cell area. CD8 T cells remain in the PALS. Mice
shown are 12 wk old. (B) Spleen sections from
age-matched (top) Tg2 MRL-lpr/lpr and (bot-
tom) VH3H9 MRL-lpr/lpr mice. VH3H9 Tg
accelerates the appearance of disrupted architec-
ture in MRL-lpr/lpr mice. Mice shown are 6 wk
old. Original magnification: 3100 (n 5 15 mice
of each genotype).1808 MRL/lpr Defect in B Cell Developmental Arrest and Follicular Exclusion
However, the CD4 T cells in the follicles of MRL-lpr/lpr
mice are not like those described in GCs as they express
Thy-1 (data not shown), a marker absent on GC T cells
(62). CD8 T cells remain tightly compacted around the
central arteriole, and neither CD4 nor CD8 T cells are
present in the MZ of VH3H9 MRL-lpr/lpr mice (Fig. 5 B).
To determine if the altered localization of CD4 T cells is
a general feature of MRL-lpr/lpr mice, or is unique to the
VH3H9 Tg, spleen sections from Tg2 MRL-lpr/lpr mice
were examined (Fig. 5, A and B). Unlike BALB/c and
MRL1/1 spleens, the Tg2 MRL-lpr/lpr spleens have CD4
T cells scattered throughout the B cell follicle (Fig. 5 A),
showing that this disrupted architecture is not limited to
VH3H9 mice. The fact that MRL-lpr/lpr and not MRL1/1
mice show disrupted architecture suggests that this alter-
ation is attributable to a block in the Fas/FasL pathway. At
the time points examined, CD4 infiltrates were not found in
other organs such as the liver or kidney (data not shown).
Although the presence of the VH3H9 Tg is not neces-
sary for the appearance of CD4 T cells in the B cell follicle,
it does accelerate the process. Age-matched VH3H9 and
Tg2 MRL-lpr/lpr mice were analyzed for CD4 T cell in-
filtrates by immunohistochemistry (Fig. 5 B). Alterations
in T/B architecture are seen as early as 4–5 wk in VH3H9
MRL-lpr/lpr spleens (Fig. 4 A, and data not shown); how-
ever, Tg2 MRL-lpr/lpr spleens show no disruption until
6–8 wk (Fig. 5 B) and it becomes more pronounced at
10–12 wk (Fig. 5 A). VH3H9 BALB/c and VH3H9
MRL1/1 mice have normal splenic architecture, suggest-
ing that the lpr mutation, not the VH3H9 Tg, is necessary
for the disruption (Fig. 4 A, and data not shown). There-
fore, in VH3H9 MRL-lpr/lpr mice, although increasing the
frequency of autoreactive B cells does not accelerate the ki-
netics or titers of serum ANAs, it does accelerate the kinet-
ics of T–B mixing in MRL-lpr/lpr mice.
Alterations in VH3H9 MRL-lpr/lpr Mice after Seroconver-
sion. In addition to noting differences in anti-dsDNA B cells
in nonautoimmune versus autoimmune mice, we also ex-
amined VH3H9 MRL-lpr/lpr mice before and after sero-
conversion to determine if any architectural alterations cor-
relate with the emergence of serum Ab. Although no
difference by flow cytometry was detected between ANA1
and ANA2 mice (Fig. 3 C), a difference was observed by
immunohistochemistry (Fig. 4, A and B). In ANA1 mice,
many darkly staining Igl1 cells are present in the PALS as
well as in the bridging channels to the red pulp (Fig. 4 B).
These cells are not obvious in ANA2 mice (data not
shown). To determine if these darkly staining cells are
AFCs, serial sections were stained for syndecan-1, a cell
surface proteoglycan that is expressed on B cells that have
differentiated into AFCs (63). The dark Igl staining cells
colocalize with syndecan-1 staining, indicating that they
are AFCs. Importantly, many Igl1/syndecan-12 cells re-
main in the B cell follicles even in ANA1 animals, suggest-
ing that not all dsDNA B cells have differentiated into
AFCs (data not shown). Syndecan-11 cells are also found
in the PALS in Tg2 MRL-lpr/lpr mice, although in this
case the vast majority are not Igl1 (Fig. 4 B), consistent
with Igk1Igl2 ANAs in the serum (Fig. 1). This localiza-
tion of AFCs to the inner T cell area, as opposed to the
bridging channels to the red pulp (also referred to by others
as the red pulp area adjacent to the T cell zone [31, 64, 65]), is
similar to that reported by Marshak-Rothstein and col-
leagues for rheumatoid factors in MRL-lpr/lpr mice (61, 66).
As an alternate approach to quantitate the number of
AFCs in the various mice, ex vivo enzyme-linked immuno-
spot assays (ELISpots) were performed (Fig. 6, A and B).
Using reagents to detect all AFCs, few to no AFCs were
detectable in spleens from young (4–6 wk) Tg2 and
VH3H9 MRL-lpr/lpr, MRL1/1, and BALB/c mice, but
Figure 6. AFCs in the spleen
from ANA2 (4–6 wk) and ANA1
(10–12 wk) Tg2 MRL-lpr/lpr,
VH3H9 MRL-lpr/lpr, and
BALB/c mice. The number of
(A) total Ig and (B) Igl AFCs
were determined by ex vivo
ELISpot. The data are presented
as the mean number of AFCs per
104 cells 6 the SD of triplicate
wells. Total Ig1 and Igl1 AFC
numbers were calculated by nor-
malizing for total B2201Ig1 and
B2201Igl1 numbers as deter-
mined by flow cytometry, respec-
tively. Presented data are from a
representative mouse of each
genotype. Total number of mice
from five experiments: n 5 5 Tg2
BALB/c; n 5 4 VH3H9 BALB/c;
n 5 4 ANA1 Tg2 and VH3H9
MRL-lpr/lpr; and n 5 2 ANA2
Tg2 and VH3H9 MRL-lpr/lpr
mice. Note that a higher number of Igl1 AFCs than total Ig1 AFCs were detected for the ANA1 VH3H9 MRL-lpr/lpr mice in this assay. This differ-
ence is attributed to a sensitivity difference in the reagents used to detect total Ig versus Igl. Therefore, although comparisons can be made for the relative
number of AFCs of a given type (i.e., between Igl1 numbers), they cannot be used to compare absolute frequencies between types (i.e., total Ig vs. Igl).1809 Mandik-Nayak et al.
became more pronounced in aged (10–12 wk) MRL-lpr/lpr
mice (Fig. 6 A and data not shown). To follow anti-dsDNA
AFCs in particular in VH3H9 MRL-lpr/lpr mice, Igl
AFCs were quantitated (Fig. 6 B). Igl AFCs were readily
detectable in older VH3H9 MRL-lpr/lpr mice. By ELISpot,
only 5–10% of the Igl1 cells in VH3H9 MRL-lpr/lpr mice
are generating AFCs. The fact that not all Igl1 cells are se-
creting Ab as shown by histology and ELISpots supports
the idea that it is a breakthrough of a fraction of the anti-
dsDNA B cells and not an overall breakdown of tolerance
that leads to serum ANAs in MRL-lpr/lpr mice.
Discussion
Several studies have documented alterations in total B and
T cell populations in autoimmune mice and SLE patients
(43, 44, 61, 67). The unique aspect of the data presented
here is that specific autoreactive B cells have been fol-
lowed, both in nonautoimmune mice and in autoimmune-
prone mice, as they develop autoantibodies. To do this we
made use of the VH3H9 H chain Tg, which increases the
frequency of anti-dsDNA B cells and allows their fate, in
the presence of nonautoreactive B cells, to be compared in
BALB/c, MRL1/1, and MRL-lpr/lpr mice. This model
has allowed for the analysis not only of endpoints such as
serum autoantibodies, but also of the B cells themselves and
the factors that influence them during the process of sero-
conversion. In this study, we have described two novel ob-
servations regarding the breakdown of tolerance in MRL-
lpr/lpr mice. The first is that MRL mice exhibit a defect in
maintaining the developmental arrest of anti-dsDNA B cells.
The second is that a deficiency in Fas allows these auto-
reactive cells to enter the B cell follicles from which they
are normally restricted. Combining these observations, we
propose that the transition of anti-dsDNA B cells from tol-
erized B cells on the BALB/c background to autoantibody-
producing cells in the MRL-lpr/lpr is a multistep process
that includes overcoming both developmental arrest and
follicular exclusion.
The MRL Background Allows Maturation of Autoreactive
Cells. It has been clearly established that autoimmunity in
MRL mice is polygenic, yet the mechanisms by which
these different loci influence autoantibody production have
not been defined (68–71). Although anti-dsDNA B cells are
tolerized in BALB/c mice as manifested by their develop-
mental arrest and accumulation at the T–B interface of the
splenic follicle (10), anti-dsDNA B cells on the MRL1/1
and MRL-lpr/lpr backgrounds are developmentally mature.
One possibility that could account for this difference is tim-
ing of initial Ag exposure. For example, if anti-dsDNA B cells
in MRL mice are not exposed to the tolerizing Ag during
their development, maturational arrest would not occur.
However, the data presented are inconsistent with this sce-
nario: for anti-dsDNA B cells in both MRL and BALB/c
mice, the level of surface Ig is low at the same develop-
mental stage in the BM. A second possibility is that al-
though anti-dsDNA B cells in both BALB/c and MRL
mice initially encounter their Ag at the same time in devel-
opment, an absence of continual Ag stimulation in the
MRL mice allows the B cells to subsequently progress to
maturity. In the HEL B cell tolerance model in the context
of bcl-2, the removal of Ag allows the development of the
anergic B cells to progress (38). However, in all the mice
studied here, anti-dsDNA B cells are uniformly Iglow in the
spleen as well as in the BM, suggesting that constant Ag ex-
posure is occurring in all cases. A third possibility, and one
we favor, is that a defect in MRL mice allows autoreactive
B cells to survive a selection checkpoint that would nor-
mally lead to developmental arrest. This is important in that
the maturation state of a B cell may translate to significant
changes in function in terms of B cell receptor–associated
intracellular signaling capabilities and subsequent B cell re-
sponsiveness (72). Mapping studies by various groups have
identified several autoimmunity-associated loci in MRL
mice (68–71). It will be important to determine if any of
these loci, together or in isolation, control the develop-
mental maturation of autoreactive B cells.
The Role of Fas in Follicular Exclusion. We observe in this
study a previously undefined connection between Fas and
the entry of cells to the B cell follicle. Comparing MRL
mice with and without the lpr defect in Fas, we find that
despite their mature status, anti-dsDNA B cells in MRL1/1
mice remain at the T–B interface, whereas in MRL-lpr/lpr
mice, they are in the B cell follicle. Exclusion from the
B cell follicle has been correlated with the decreased sur-
vival of B cells (58). However, studies using bcl-2 Tgs have
shown that this correlation is not absolute, as simply in-
creasing a B cell’s life span does not alone alter the localiza-
tion of anti-HEL B cells from the T–B interface (27). The
data from the present study indicate that Fas can play an
important role in determining follicular entry; what re-
mains to be discovered is the mechanism by which it exerts
this effect. A deficiency in Fas could act directly on the sur-
vival of the anti-dsDNA B cells. Alternatively, lack of Fas
could have an indirect effect through the shaping of the
peripheral T and B cell repertoires.
The lack of Fas could translate into an alteration in the
availability of T cell help. It has been clearly established that
T cells are required for the generation of autoantibodies in
MRL-lpr/lpr mice (73–75). Additionally, it has been sug-
gested that Ag-experienced B cells, such as the anti-dsDNA
B cells followed here, are held at the T–B interface in the ab-
sence of T cell help (39, 58). In light of this idea, one possi-
ble interpretation of our results is that Fas normally plays a
crucial role in eliminating the autoreactive T cell population.
In its absence, a fundamental shift occurs in the T cell reper-
toire such that autoreactive T cell help is now available, and
autoreactive B cells are given the signals they need to pro-
ceed past the T–B interface. The data presented here argue
against this possibility. The anti-dsDNA B cells are found
peppered throughout the B cell follicle and appear not to be
proliferating (data not shown). If they had received T cell
help, we would have expected to observe either (a) the com-
paction of B cells in follicular GCs, or (b) the formation of
AFCs (31). Although at later time points (mice .8 wk) we
do see evidence of AFCs, at the early time points (4–7 wk)1810 MRL/lpr Defect in B Cell Developmental Arrest and Follicular Exclusion
dsDNA B cells appear exclusively in the follicles. Thus, the
effect of Fas on follicular entry seems unlikely to be mediated
solely through an effect on T cell help.
Alternatively, Fas could regulate follicular entry through
its functions on the B cell itself. For example, Rathmell and
colleagues have shown that anergic B cells, far from being
rescued by T cell help, are killed in a Fas-dependent man-
ner (76, 77). In the absence of Fas, then, it is possible that
anti-dsDNA B cells would not die and thus would be able
to proceed into the B cell follicle. One prediction from this
is that anti-dsDNA B cells in Fas wild-type animals would
have a reduced life span. Experiments are currently under-
way to determine if the life span of anti-dsDNA B cells is
reduced in MRL1/1 compared with MRL-lpr/lpr mice.
Again, however, if T cell help were present in the absence
of Fas, we would expect to see evidence of further differ-
entiation of the anti-dsDNA B cells in young MRL-lpr/lpr
mice. Interestingly, experiments using TCR2/2 mice, in the
context of the HEL B cell tolerance model, have shown
that T cells are not required to maintain follicular exclusion
(78). Therefore, if a signal through Fas on the B cell is what
restricts it to the T–B interface, other FasL-expressing cells
would be required to deliver that signal.
A scenario that is consistent with our data is that the
deficiency in Fas is affecting the proportion of autoreactive
B cells in the peripheral B cell repertoire and, as such, alters
B cell localization. Studies in the HEL system indicate that
changes in the B cell repertoire can affect the localization of
autoreactive B cells. In mice where anergic anti-HEL B cells
make up the vast majority of the B cell population, they are
present in the B cell follicle; however, when nonautoreac-
tive B cells are also present, the anergic B cells are excluded
from the B cell follicle (27, 58). If Fas plays a role in elimi-
nating autoreactive B cells, then the lpr mutation could af-
fect the proportion of autoreactive B cells in the periphery
such that, instead of the majority of competing B cells be-
ing nonautoreactive, the anti-dsDNA B cells are in an en-
vironment with mostly other autoreactive B cells. There-
fore, anti-dsDNA B cells in MRL-lpr/lpr mice would be
present in the B cell follicle due to lack of competition and
not because they are missing a signal through Fas to restrict
their entry. Altering the composition of the B cell reper-
toire by transfer experiments of dsDNA B cells from
VH3H9 MRL-lpr/lpr mice into MRL-lpr/lpr mice where
the B cells express a nonautoreactive Ig Tg (23) should al-
low us to discern if the addition of competitive B cells now
results in follicular exclusion of the anti-dsDNA B cells.
An additional component that must be considered is the
role of Fas in Ag composition. The role of Ag in MRL-lpr/lpr
autoantibody production remains controversial. BM chi-
mera and allophenic experiments, mixing lpr/lpr and Fas
wild-type cells, have suggested that intrinsic B and T cell
defects in lpr/lpr mice, and not alterations in Ag milieu, are
responsible for autoantibody production (79–82). How-
ever, the interpretation of these results is complicated. lpr/lpr
T cells are known to express elevated levels of FasL (83,
84), and it is distinctly possible that the autoreactive non-
lpr/lpr B cells in the chimeras, susceptible to Fas-mediated
death upon activation, are simply triggered to die before
they can contribute to autoantibody levels. Therefore, it
remains a possibility that eliminating Fas-mediated death
alters the antigenic make-up of MRL-lpr/lpr mice. Consis-
tent with this, studies by Rosen and colleagues have shown
that some of the nuclear Ags targeted in SLE are packaged
into discrete blebs at the surface of apoptotic cells (85).
They have further demonstrated that triggering apoptotic
pathways by different stimuli generates unique substrate
fragments that can then be clustered in these blebs (86).
Preferential use of one pathway over another, as could oc-
cur in Fas-deficient MRL mice, would potentially alter the
ability to produce and display tolerogenic or immunogenic
epitopes. The fact that dsDNA B cells from both MRL1/1
and MRL-lpr/lpr mice are uniformly Iglow suggests that
both are encountering a similar amount of Ag. However, it
may be that a difference in antigenic context determines
whether a B cell enters the follicle, as in MRL-lpr/lpr mice,
or is held at the T–B interface, as in MRL1/1 mice. Be-
cause of the potential significance of this issue, experiments
are currently underway to explore the nature of the in vivo
Ag recognized by these anti-dsDNA B cells.
The Role of Fas in Regulating Entry of T Cells to the B Cell
Follicle. In examining the localization of anti-dsDNA B
cells, we have identified a unique histological feature of
CD4 T cells in both Tg2 and VH3H9 MRL-lpr/lpr mice.
A subpopulation of CD4 T cells, which normally are lo-
cated in a discrete area around the central arteriole, have
infiltrated the B cell follicle. The lack of this infiltrate in
Tg2 and VH3H9 MRL1/1 mice suggests that the ab-
sence of a Fas–FasL interaction is the determining factor. In
VH3H9 MRL-lpr/lpr mice, the T cell splenic architecture
is disrupted as early as 4 wk of age (before we see evidence
of DN T cells) and becomes more apparent as the mice
age. Interestingly, increasing the frequency of autoreactive
B cells by the presence of the VH3H9 Tg, while not accel-
erating seroconversion, does accelerate the appearance of
T–B mixing. Why a subpopulation of T cells resides in the
B cell follicle in VH3H9 MRL-lpr/lpr mice is unclear, but
the follicular localization of CD4 T cell infiltrates occurs in
mice that also have follicular anti-dsDNA B cells. Our
working model is that the increased frequency of autoreac-
tive B cells in the VH3H9 Tg mouse plays a role in accel-
erating the influx of CD4 T cells. There is precedent for
B cells, in general, affecting the activation status of T cells
in MRL-lpr/lpr mice: B cell–deficient MRL-lpr/lpr mice
do not have as many activated/memory T cells as B cell–
sufficient MRL-lpr/lpr mice (28). To explore this idea fur-
ther, we are examining the spleens of MRL-lpr/lpr mice
carrying Ig Tgs in the absence of their cognate Ag (23). We
would predict that the infiltration of T cells would occur at
a decreased rate in mice with a B cell repertoire skewed
away from autoreactivity. Alternatively, it may be the infil-
trating CD4 T cells that allow the anti-dsDNA B cells to
enter the follicle. To independently regulate the follicular
entry of CD4 T cells and dsDNA B cells, we are breeding
the VH3H9 Tg onto MHC class II–deficient MRL-lpr/lpr
mice (74). These mice will allow us to determine if the al-1811 Mandik-Nayak et al.
tered localization of VH3H9/l B cells is dependent on the
presence of CD4 T cells.
Autoantibody Production. This study has allowed us to
compare the phenotype of the anti-dsDNA B cells in
MRL-lpr/lpr mice before and after seroconversion. Even
before seroconversion, the anti-dsDNA B cells are devel-
opmentally mature and in the B cell follicle. Furthermore,
using a decreased level of surface Ig to indicate Ag encoun-
ter (3, 10–12, 35–38), anti-dsDNA B cells are Iglow in the
BM, spleen, and LNs, suggesting continual Ag exposure,
beginning in the BM. The consistent histological difference
between VH3H9 MRL-lpr/lpr mice before and after sero-
conversion is the presence of Igl AFCs in serum Igl
ANA1 animals. We note two striking characteristics of this
AFC formation. The first is that, while mice immunized
with model Ags, such as (4-hydroxy-3-nitrophenyl)acetyl
(NP), form AFCs in the bridging channels to the red pulp
(31, 64, 65), the VH3H9/Igl AFCs are, in addition to be-
ing in the bridging channels, also located in the PALS. This
altered localization of AFCs is consistent with that previ-
ously reported by Marshak-Rothstein and colleagues for
rheumatoid factor AFCs in MRL-lpr/lpr mice (61, 66).
Whether this localization of AFCs to the PALS is restricted
to autoreactive B cells or extends to AFCs in response to
foreign Ags is currently under study. The second difference
is that even in serum Igl ANA1 animals, not all of the Igl
B cells become AFCs, suggesting a breakthrough of only
some autoreactive B cells and not a global breakdown that
would affect the population as a whole. Therefore, we have
segregated initial exposure of Ag and entry into the follicle
from terminal differentiation into AFCs.
Conclusions. In summary, the factors that are required
to transform an autoreactive B cell population from a toler-
ant one to one producing Ab are clearly complex. This
study has compared the phenotype and splenic localization
of a population of anti-dsDNA B cells in nonautoimmune
mice with anti-dsDNA B cells in autoimmune MRL1/1
and MRL-lpr/lpr mice. BALB/c mice actively regulate
anti-dsDNA B cells as manifested by their developmental
arrest, retention at the T–B interface, and lack of anti-
dsDNA Ab in the serum. In MRL-lpr/lpr mice where anti-
dsDNA Ab is present in the serum, the anti-dsDNA B cells
are no longer developmentally arrested or excluded from
the B cell follicle. Anti-dsDNA B cells in MRL1/1 mice
are also not developmentally arrested; however, they re-
main at the T–B interface. This allows us to assign a defect
in maturational arrest to the MRL genetic background.
The maturation state of B cells may have profound effects
on their life span and ability to be reactivated. Additionally,
in this model, a defect in Fas is needed for the B cells to en-
ter the follicle. However, even Fas-deficient B cells require
an additional factor to become AFCs, as young VH3H9
MRL-lpr/lpr mice, where the l1 B cells are mature and in
the follicle, are serum2. Changes in T cell help or Ag pre-
sentation may be required for seroconversion. Interestingly,
a defect in Fas also leads to an infiltration of CD4 T cells into
the B cell follicle. What role this infiltrate plays in the pro-
duction of autoantibodies is unknown. Given the require-
ment for CD4 T cells in the production of autoantibodies in
MRL-lpr/lpr mice (73–75), it will be important to determine
the specificity of these infiltrating CD4 T cells.
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